Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,27 +2,26 @@
2	2	{{toc/}}
3	3	{{/box}}
4	4
5		-Summary
	5	+= Summary =
6	6
7		-Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer.
	7	+* Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer.
	8	+* Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve
8	8
9		-Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve
10	10
	11	+[[image:APVO0.png||height="324" width="718"]]
11	11
12	12
13		-Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer.
14	14
	15	+Aptevo Therapeutics Inc (Nasdaq: APVO) is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer.
15	15
16	16
17		-Recent Developments
	18	+= Recent Developments =
18	18
19		-Aptevo Therapeutics Plans a Phase 2 Trial in 2H23
	20	+**Aptevo Therapeutics Plans a Phase 2 Trial in 2H23**
20	20
21		-December 12, 2022; Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve
	22	+December 12, 2022; Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve{{footnote}}https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/100-clinical-benefit-rate-achieved-phase-1b-trial-evaluating{{/footnote}}
22	22
23		-[[https:~~/~~/aptevotherapeutics.gcs-web.com/news-releases/news-release-details/100-clinical-benefit-rate-achieved-phase-1b-trial-evaluating>>url:https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/100-clinical-benefit-rate-achieved-phase-1b-trial-evaluating]]
24	24
25		-
26	26	Aptevo Therapeutics Inc; announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate (CBR) in venetoclax treatment naïve AML patients. The data, which was presented in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.
27	27
28	28
...	...	@@ -32,17 +32,22 @@
32	32	In the Phase 1b trial cohort 2, a total of 16 response-evaluable patients received the combination therapy of venetoclax and azacitidine with APVO436 and 75% experienced clinical benefit. 100% of patients in this cohort who had not received venetoclax previously, experienced clinical benefit; a favorable outcome with respect to a variety of response categories including CR, CRi and MLFS.
33	33
34	34
	34	+= Pipeline =
35	35
	36	+ADAPTIR™ and ADAPTIR-FLEX™ Therapeutic Canididate Portfolio{{footnote}}https://aptevotherapeutics.com/pipeline/{{/footnote}}
36	36
37		-Financial Highlights
38	38
39		-Third Quarter 2022 Results
	39	+[[image:APVO1.png]]
40	40
41		-November 10, 2022; Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
42	42
43		-[[https:~~/~~/aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-reports-third-quarter-2022-financial-results>>url:https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-reports-third-quarter-2022-financial-results]]
44	44
	43	+= Financial Highlights =
45	45
	45	+**Third Quarter 2022 Results**
	46	+
	47	+November 10, 2022; Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights{{footnote}}https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-reports-third-quarter-2022-financial-results{{/footnote}}
	48	+
	49	+
46	46	Cash Position: Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022. This includes $0.4 million of restricted cash that was released in October 2022.
47	47
48	48
...	...	@@ -68,49 +68,45 @@
68	68
69	69
70	70
71		-Company Overview
	75	+= Company Overview =
72	72
73		-
74	74	Aptevo is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Aptevo has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. The company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using its ADAPTIR™ modular protein technology platform. The company's preclinical candidate APVO442 was developed using its ADAPTIR-FLEX™ modular protein technology platform.
75	75
	79	+
76	76	The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells. ADAPTIR and ADAPTIR-FLEX are both modular platforms, which gives it the flexibility to generate immunotherapeutic candidates with a variety of mechanisms of action.
77	77
78	78
	83	+[[image:APVO2.png]]
79	79
80		-Technology
81	81
82	82
83		-Aptevo is a clinical stage biotechnology company focused on development of novel immunotherapies using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies.
	87	+== Technology ==
84	84
85		-[[https:~~/~~/aptevotherapeutics.com/our-technology/>>url:https://aptevotherapeutics.com/our-technology/]]
	89	+Aptevo is a clinical stage biotechnology company focused on development of novel immunotherapies using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies.{{footnote}}https://aptevotherapeutics.com/our-technology/{{/footnote}}
86	86
87	87
88		-ADAPTIR-FLEX™ Technology
	92	+=== ADAPTIR-FLEX™ Technology ===
89	89
90	90	ADAPTIR-FLEX technology extends advantages of ADAPTIR technology to create protein therapeutics with varied specificity and valency and potentially new modes of action.
91	91
92	92
93		-Current Pipeline Candidates using ADAPTIR-FLEX Technology:
	97	+**Current Pipeline Candidates using ADAPTIR-FLEX Technology:**
94	94
95		-APVO442 (PSMA x low affinity CD3)
	99	+* APVO442 (PSMA x low affinity CD3)
96	96
97	97
	102	+=== ADAPTIR™ Technology ===
98	98
99		-ADAPTIR™ Technology
100		-
101		-Modular and Flexible
102		-
103	103	Demonstrated ability to produce monospecific and bispecific drug candidates. Leverages IgG1 Fc to form homodimeric bispecific molecules. Optimized to minimize proteolytic cleavage and post-translational modifications
104	104
105	105
	107	+**Current Pipeline Candidates using ADAPTIR Technology:**
106	106
107		-Current Pipeline Candidates using ADAPTIR Technology:
	109	+* APVO436 (CD123 x CD3): Clinical candidate for the treatment of AML, MDS
	110	+* ALG.APV-527 (41BB x 5T4): Preclinical candidate, planned to advance into clinic for the treatment of solid tumors expressing 5T4
	111	+* APVO603 (41BB x OX40): Preclinical candidate that actives two costimulatory receptors on immune cells for the treatment of multiple solid tumor indications
108	108
109		-APVO436 (CD123 x CD3): Clinical candidate for the treatment of AML, MDS
110	110
111		-ALG.APV-527 (41BB x 5T4): Preclinical candidate, planned to advance into clinic for the treatment of solid tumors expressing 5T4
	114	+= References =
112	112
113		-APVO603 (41BB x OX40): Preclinical candidate that actives two costimulatory receptors on immune cells for the treatment of multiple solid tumor indications
114		-
115		-
116		-References
	116	+{{putFootnotes/}}